The interim results on the first 415 patients randomized in the phase 3 ALPINE study showed a significantly better response for zanubrutinib compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic leukemia, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds.
The interim results on the first 415 patients randomized in the phase 3 ALPINE study showed a significantly better response for zanubrutinib compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic leukemia, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds and honorary consultant hematologist at Leeds Teaching Hospitals NHS Trust.
What do the interim results of the phase 3 ALPINE study of zanubritinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic leukemia show so far?
The ALPINE study compared zanubrutinib with ibrutinib, which are second-generation Bruton tyrosine kinase (BTK) inhibitors. The study is a large trial with 652 patients, but the interim results being presented at the European Hematology Association meeting are of the first 415 patients who were randomized.
The primary end point was overall response rate, which allowed for the trial to be reported earlier, and the follow-up is relatively short. The overall response was significantly better for zanubrutinib compared with ibrutinib at the 12-month time point, Hillmen explained. The outcome of the progression-free survival was also in favor of zanubrutinib, he added.
“As yet, not a significant difference in overall survival, although there is a trend to watch that space,” Hillmen said. “Also there’s a reduction, a significant reduction, in atrial fibrillation from 10% to 2.5% for zanu[brutinib].”
The study will be followed longer, the numbers will change, and there will be new adverse effects.
“There’s been a difference in hypertension, which is interesting, but that might be to do with the short follow-up,” Hillmen said. “So, I think we need further follow-up for the ALPINE study.”
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More